Mads A.
- Country
- Denmark
- Department
- Oncology
Research Overview
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
- A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
- Evaluation of Perioperative Pembrolizumab and Enfortumab Vedotin with Cystectomy Versus Cystectomy Alone in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Data & Insights
Has run more than one trial at 77 of 231 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating various forms of urological cancers, with particular emphasis on bladder cancer and its advanced manifestations. Their expertise extends to managing both early-stage and metastatic disease conditions.
- Muscle-invasive bladder cancer
- Metastatic urothelial carcinoma
- Advanced renal cell carcinoma
The investigator's work encompasses comprehensive treatment approaches for urological malignancies, including surgical and systemic therapeutic interventions.
Immunotherapy Applications
Focus on implementing innovative immunotherapy treatments for urological cancers, particularly utilizing checkpoint inhibitors in various treatment settings.
- PD-1/PD-L1 targeted therapies
- Combination immunotherapy approaches
- Perioperative immunotherapy protocols
The investigator works with various immunotherapeutic agents in both monotherapy and combination treatment strategies.
Treatment Innovation
Involvement in developing novel therapeutic approaches for urological cancers, including personalized treatment strategies and biomarker-guided therapies.
- Circulating tumor DNA monitoring
- Combined modality treatments
- Advanced surgical interventions
The investigator integrates molecular diagnostics with therapeutic interventions to optimize treatment outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.